Is Teclistamab reimbursable by medical insurance?

Teritusumab (Teclistamab-cqyv) is an innovative therapeutic drug mainly used to treat relapsed or refractory multiple myeloma (MM). As a bispecific antibody drug, teritusumab has shown strong effects in cancer treatment, especially for patients who have experienced multiple treatment options but still cannot effectively control their disease. Although teritusumab has significant clinical application effects, there are still certain challenges in the medical insurance coverage of this drug in China.

The generic drug teritusumab is currently on the Chinese market, but has not yet been included in the national medical insurance directory. This means that patients need to pay for the drug out of pocket, and its price is relatively high, usually between 30,000 to 40,000 yuan. For some patients, the cost of medications can become a financial burden of treatment. Although teritusumab has not yet been included in medical insurance, as the therapeutic effect continues to be proven and the demand for multiple myeloma treatment increases, new policies may include it in medical insurance in the future. This change will greatly reduce the financial burden on patients and enable more patients to obtain this effective targeted therapy.

Currently, if patients need treatment with teritusumab, they may need to purchase it through hospitals, pharmacies or specialist clinics. Due to the higher price, patients can consult the relevant drug supplier when purchasing to find out whether there is a patient assistance program or insurance coverage to reduce the cost of treatment.

Teritusumab, as a new type of immunotherapy drug, has demonstrated excellent results in the treatment of relapsed or refractory multiple myeloma due to its unique bispecific mechanism of action. Although the drug is relatively expensive and not yet covered by medical insurance, its remarkable efficacy provides a new treatment option for patients with multiple myeloma. Patients should strictly follow the storage conditions of the drug during use and avoid any situation that may affect the efficacy of the drug.

Keyword tags: teritolumab, Teclistamab, multiple myeloma, medical insurance, drug prices, patient assistance programs, generic drugs, medical insurance reimbursement, targeted therapy

Reference materials:https://www.ema.europa.eu/en/documents/product-information/tecvayli-epar-product-information_en.pdf